JP2021513965A5 - - Google Patents

Info

Publication number
JP2021513965A5
JP2021513965A5 JP2020543314A JP2020543314A JP2021513965A5 JP 2021513965 A5 JP2021513965 A5 JP 2021513965A5 JP 2020543314 A JP2020543314 A JP 2020543314A JP 2020543314 A JP2020543314 A JP 2020543314A JP 2021513965 A5 JP2021513965 A5 JP 2021513965A5
Authority
JP
Japan
Prior art keywords
cancer
composition according
compound
approximately
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020543314A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021513965A (ja
JP7417527B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/018009 external-priority patent/WO2019161054A1/en
Publication of JP2021513965A publication Critical patent/JP2021513965A/ja
Publication of JP2021513965A5 publication Critical patent/JP2021513965A5/ja
Priority to JP2023177591A priority Critical patent/JP2023171662A/ja
Application granted granted Critical
Publication of JP7417527B2 publication Critical patent/JP7417527B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020543314A 2018-02-16 2019-02-14 アゾロピリミジン化合物による投薬 Active JP7417527B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023177591A JP2023171662A (ja) 2018-02-16 2023-10-13 アゾロピリミジン化合物による投薬

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862710394P 2018-02-16 2018-02-16
US62/710,394 2018-02-16
PCT/US2019/018009 WO2019161054A1 (en) 2018-02-16 2019-02-14 Dosing with an azolopyrimidine compound

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023177591A Division JP2023171662A (ja) 2018-02-16 2023-10-13 アゾロピリミジン化合物による投薬

Publications (3)

Publication Number Publication Date
JP2021513965A JP2021513965A (ja) 2021-06-03
JP2021513965A5 true JP2021513965A5 (cg-RX-API-DMAC7.html) 2022-02-21
JP7417527B2 JP7417527B2 (ja) 2024-01-18

Family

ID=67619607

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020543314A Active JP7417527B2 (ja) 2018-02-16 2019-02-14 アゾロピリミジン化合物による投薬
JP2023177591A Pending JP2023171662A (ja) 2018-02-16 2023-10-13 アゾロピリミジン化合物による投薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023177591A Pending JP2023171662A (ja) 2018-02-16 2023-10-13 アゾロピリミジン化合物による投薬

Country Status (9)

Country Link
US (2) US11478479B2 (cg-RX-API-DMAC7.html)
EP (1) EP3755333A4 (cg-RX-API-DMAC7.html)
JP (2) JP7417527B2 (cg-RX-API-DMAC7.html)
KR (1) KR102823186B1 (cg-RX-API-DMAC7.html)
CN (1) CN111818923A (cg-RX-API-DMAC7.html)
AU (1) AU2019222747B2 (cg-RX-API-DMAC7.html)
CA (1) CA3090922A1 (cg-RX-API-DMAC7.html)
TW (1) TWI879727B (cg-RX-API-DMAC7.html)
WO (1) WO2019161054A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3090922A1 (en) 2018-02-16 2019-08-22 Arcus Biosciences, Inc. Dosing with an azolopyrimidine compound
EP3823614A4 (en) 2018-07-18 2022-03-30 Arcus Biosciences, Inc. SOLID FORMS OF AN AZOLOPYRIMIDINE COMPOUND
ES3070946T3 (en) 2019-03-12 2026-06-18 Arcus Biosciences Inc Treatment of an oncogenene driven cancer having a kras or egfr mutation by decreasing adenosine production or antagonizing adenosine activation
CA3135487A1 (en) 2019-03-29 2020-10-08 Arcus Biosciences, Inc. Treatment of cancer utilizing an identified adenosine fingerprint
BR112021022538A2 (pt) 2019-06-06 2021-12-28 Arcus Biosciences Inc Processos para preparar compostos de aminopirimidina
CN113121502A (zh) * 2019-12-31 2021-07-16 山东铂源生物医药有限公司 一种杂芳烃类化合物、中间体、组合物及应用
KR102646627B1 (ko) * 2021-03-24 2024-03-13 주식회사 스탠다임 아데노신 a2a 수용체 및 아데노신 a2b 수용체의 이중 길항제, 및 이의 용도
WO2024097736A1 (en) * 2022-11-02 2024-05-10 Arcus Biosciences, Inc. Processes for preparing azolopyrimidine compounds

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI330183B (cg-RX-API-DMAC7.html) 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
CA2551944A1 (en) 2003-12-15 2005-06-30 Almirall Prodesfarma Ag 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール,インク. Gitr結合分子およびその使用
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
IN2015DN02826A (cg-RX-API-DMAC7.html) 2009-09-03 2015-09-11 Merck Sharp & Dohme
DK2510010T3 (en) 2009-12-10 2015-12-14 Hoffmann La Roche Antibodies that bind to human CSF1R extracellular domain 4 and their use
RU2617971C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
ES2365960B1 (es) * 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
EP3943154A1 (en) 2010-05-04 2022-01-26 Five Prime Therapeutics, Inc. Antibodies that bind csf1r
NZ729044A (en) 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
DE102011008352A1 (de) 2011-01-12 2012-07-12 Merck Patent Gmbh 5-([1,2,3]Triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidinderivate
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
MX356337B (es) 2011-12-15 2018-05-23 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
MX2014008961A (es) 2012-02-06 2014-10-14 Genentech Inc Composiciones y metodos para utilizar inhibidores de csf1r.
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
KR20150018533A (ko) 2012-05-11 2015-02-23 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
EA036954B1 (ru) 2015-04-08 2021-01-19 Льюис Энд Кларк Фармасьютикалз, Инк. Ксантинзамещенные алкинилкарбаматы/обращенные карбаматы в качестве антагонистов a2b
WO2017025918A1 (en) 2015-08-11 2017-02-16 Novartis Ag 5-bromo-2,6-di-(lh-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer
MX389798B (es) * 2017-01-20 2025-03-20 Arcus Biosciences Inc Azolopirimidina para el tratamiento de trastornos relacionados con el cáncer.
US20200055883A1 (en) 2017-02-17 2020-02-20 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides derivative for the treatment of cancer
JP6453507B2 (ja) 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Mcl−1タンパク質を阻害する化合物
MX2019010302A (es) 2017-03-30 2019-11-21 Hoffmann La Roche Isoquinolinas como inhibidores de hpk1.
AR111307A1 (es) 2017-03-30 2019-06-26 Takeda Pharmaceuticals Co Derivados de 1’,2’-dihidroespiro[ciclohexan-1,3’-indol] o 1’,2’-dihidroespiro[ciclohexan-1,3’-pirrolo[3,2-b]piridina] como inhibidores de hexakisfosfato quinasa
US20200172628A1 (en) * 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
CA3090922A1 (en) 2018-02-16 2019-08-22 Arcus Biosciences, Inc. Dosing with an azolopyrimidine compound

Similar Documents

Publication Publication Date Title
JP6066421B2 (ja) 癌の治療のための低酸素活性化プロドラッグおよび血管新生阻害剤の投与方法
JP2022535120A5 (cg-RX-API-DMAC7.html)
JP2021531314A5 (cg-RX-API-DMAC7.html)
JP2019516711A5 (cg-RX-API-DMAC7.html)
TWI641374B (zh) 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑
JP2023530456A5 (cg-RX-API-DMAC7.html)
TWI869511B (zh) 治療癌症之方法
JP2014530181A5 (cg-RX-API-DMAC7.html)
Nourbakhsh et al. Biological and pharmacological activities of noscapine: Focusing on its receptors and mechanisms
JP2024502446A5 (cg-RX-API-DMAC7.html)
JP2021113228A (ja) 重度腎機能障害を有する癌患者に対する治療方法
JP2017516827A5 (cg-RX-API-DMAC7.html)
US20160067248A1 (en) Combinations
JP2020521786A5 (cg-RX-API-DMAC7.html)
JP2016502540A5 (cg-RX-API-DMAC7.html)
JP2024538719A5 (cg-RX-API-DMAC7.html)
WO2004081012A1 (ja) 抗腫瘍効果増強剤及び抗腫瘍剤
CN110522753A (zh) 一种新型抗肿瘤药物组合物、制剂和应用
JP2018511642A5 (cg-RX-API-DMAC7.html)
TW202114682A (zh) Mcl-1抑制劑與乳癌標準療法之組合,其用途及醫藥組合物
JP2022526525A5 (cg-RX-API-DMAC7.html)
CA2569739C (en) Antitumor effect potentiator, antitumor preparation, and method for treating cancer
JP2023514426A5 (cg-RX-API-DMAC7.html)
EP2826482A1 (en) Novel antitumor agent comprising combination of three agents
JP2024520307A5 (cg-RX-API-DMAC7.html)